Anti-vascular endothelial growth factor (anti-VEGF) agents have recently been introduced as potential modulators of the post-filtration surgery healing process. Newer anti-VEGF agents have become popular as intravitreal injections for choroidal and retinal neovascular disease, which has lead to their early adoption as wound modulators for glaucoma surgery. This article describes common anti-VEGF agents, reviews preclinical and clinical reports exploring their use for glaucoma surgery and suggests steps for developing a broader knowledge base to better understand their utility for the practicing glaucoma surgeon.